Diageo plc vs McKesson Corporation — how do they compare? Diageo plc trades at $87.58 (market cap $47.54B), while McKesson Corporation trades at $930 (market cap $106.14B). The key difference: McKesson Corporation is far larger — about 2.2× Diageo plc's market cap, and Diageo plc pays the higher dividend (2.36%). Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and McKesson Corporation for 74 Days on average.
| DEO | MCK | |
|---|---|---|
Market Cap | $47.54B | $106.14B |
Volume | 1,824,704 | 794,405 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $995.69 |
52-Week Low | $72.47 | $725.17 |
Typical Hold Time | 66 Days | 74 Days |
Enterprise Value | $67.96B | $112.67B |
Dividend Yield | 2.36% | 0.41% |
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $84.73, down slightly by 0.06% on the day, with a bearish technical signal from moving averages. The company shows solid profitability with a 59.47% gross margin and has beaten EPS estimates in the last three quarters. Recent news highlights marketing initiatives and a CFO transition planned for 2027, while analyst consensus leans positive with 49% buy ratings.
The outlook is mixed: cost-cutting and brand investments support a turnaround, but declining 2026 revenue and net income projections pose risks. Valuation ratios like P/E of 27.19 suggest premium pricing, requiring execution success to justify. Key risks include U.S. market challenges and regulatory scrutiny in regions like India.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →